Get more replies from employers
Send a job-specific resume in minutes.
Zealand Pharma A/S in Denmark is seeking a QA Manager for complaint management to build and strengthen our complaint systems and oversee processes for both clinical and marketed products. You will work with Manufacturing QA, the CMC organization, CMOs and Partners to ensure compliant, scalable, and business‑driving improvements across the quality systems supporting complaint handling.
This hands‑on role combines process ownership with continuous improvement, requiring strong communication,
Does it excite you to work with Complaint Management, and do you have experience within cross-functional CMC collaboration and CMO and Partner communication? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
Your new position As our QA Manager for complaint management, you will play a crucial role in building and strengthening our complaint management systems, and handling complaint processes regarding both clinical products as well as marketed products. You will work closely with Manufacturing QA, the CMC organization internally, CMOs and Partners to ensure that the process supports both compliance and the needs of the business. The role combines hands‑on complaint management with process ownership and continuous improvement of the quality systems supporting complaint handling processes for both clinical products and marketed products. This is an exciting opportunity to take ownership of an important quality process and contribute to how we develop efficient, compliant, and scalable ways of working across the organization.
You will join Quality Systems within QA, a team of 9 colleagues responsible for developing, maintaining, and continuously improving our Quality Management System and the digital solutions supporting it. The team works across QA and the wider organization to ensure robust, efficient, and scalable quality processes. Our responsibilities include Quality Management System processes, quality documentation, training, process management, and the continued development of our digital Quality Systems, including Veeva Quality Vault.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let’s bond and be bold.
For further information, please contact QA Director Kamilla Vagtborg, KVagtborg@zealandpharma.com.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.